tiprankstipranks

Legend Biotech Reports Strong CARVYKTI® Sales for Q1 2025

Story Highlights

An update from Genscript Biotech ( (HK:1548) ) is now available.

Legend Biotech, an associate of Genscript Biotech, announced that CARVYKTI® generated approximately US$369 million in net trade sales for the quarter ended March 31, 2025. This announcement highlights the product’s strong market performance and its potential impact on the company’s financial health and industry standing.

More about Genscript Biotech

Genscript Biotech Corporation is a biotechnology company incorporated in the Cayman Islands, focusing on innovative biopharmaceutical products and services. Its associate, Legend Biotech, is listed on the Nasdaq Global Select Market in the U.S. and collaborates with Janssen Biotech, Inc. to develop and market CARVYKTI®, a pharmaceutical product.

YTD Price Performance: 2.36%

Average Trading Volume: 4,480

Technical Sentiment Signal: Buy

Current Market Cap: $2.95B

Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App